Lithium Toxicity
Article Details
- CitationCopy to clipboard
Hedya SA, Swoboda HD
Lithium Toxicity
.
- PubMed ID
- 29763168 [ View in PubMed]
- Abstract
The drug of choice for recurrent bipolar illness management remains to be lithium. Lithium, a monovalent cation similar to sodium with an unknown mechanism, was first approved by the U.S. Food and Drug Administration (FDA) as a mood-stabilizing medication for treatment of mania in the 1970s. Lithium is a very powerful, antimanic medication with a narrow therapeutic index. PharmacodynamicsLithium's physiologic role is unknown, and its mechanism is not well understood; however, some proposed mechanisms include: Hindering norepinephrine release and enhancing its reuptake. Producing brain inositol depletion, leading to reduced responsiveness to alpha-adrenergic stimulation. REducing neuronal responsiveness to neurotransmitters due to inhibitory effects on adenylate cyclase and G proteins vital for ion channel opening. Stimulating serotonin release from the hippocampus. Being a cation, acting similar to potassium and sodium, thus affecting ion transport and cell membrane potential.
DrugBank Data that Cites this Article
- Drugs
- Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareLithium carbonateValsartan The serum concentration of Lithium carbonate can be increased when it is combined with Valsartan. Lithium carbonateOlmesartan The serum concentration of Lithium carbonate can be increased when it is combined with Olmesartan. Lithium carbonateLosartan The serum concentration of Lithium carbonate can be increased when it is combined with Losartan. Lithium carbonateCandesartan cilexetil The serum concentration of Lithium carbonate can be increased when it is combined with Candesartan cilexetil. Lithium carbonateEprosartan The serum concentration of Lithium carbonate can be increased when it is combined with Eprosartan.